CANCER SECOND OPINIONS IN CHINA:
ZHONGSHAN, FUDAN & SUN YAT-SEN
Three of the world's highest-volume cancer centres — each with subspecialist expertise developed over decades of treating diseases that occur at higher frequency in Chinese patients than anywhere else.
analyticsAt a Glance
- check_circleZhongshan Hospital Shanghai is China's leading hepatocellular carcinoma and liver surgery centre
- check_circleFUSCC (Fudan University Shanghai Cancer Center) is China's most internationally recognised dedicated cancer hospital
- check_circleSun Yat-sen University Cancer Center Guangzhou is Asia's foremost nasopharyngeal and head and neck cancer centre
- check_circleCancerFax manages the full referral, translation, and logistics process for international second opinion patients at all three
Why China's Cancer Centres Are a Unique Second Opinion Resource
China's top cancer centres have developed subspecialist expertise in tumour types that occur at unusually high frequency in Chinese and East Asian populations — hepatocellular carcinoma, gastric cancer, nasopharyngeal carcinoma, oesophageal cancer, and lung cancer. The volume of these cases seen at China's leading centres produces pattern recognition, outcome data, and treatment experience that does not exist at equivalent scale anywhere else in the world.
“For hepatocellular carcinoma, nasopharyngeal cancer, and gastric cancer, China's top centres have seen more cases in the past five years than most Western centres will see in their institutional history.”
Volume-Driven Subspecialist Expertise
Zhongshan Hospital performs over 4,000 liver resections per year — a volume that produces surgical and oncological expertise impossible to replicate at lower-volume centres. SYSUCC treats more nasopharyngeal carcinoma cases than any centre outside Southern China, where NPC incidence is 20–50× higher than in Western populations.
Access to China-Approved Novel Agents
Several targeted therapies, immunotherapy combinations, and locoregional treatment modalities have been approved in China ahead of Western regulators — particularly in HCC (lenvatinib + pembrolizumab combinations), gastric cancer (HER2-directed ADCs), and liver-directed therapies. Chinese centre second opinions identify these options for patients who may not be aware of them.
Three Leading China Cancer Centres: Strengths and Focus
Each of China's top three oncology centres has distinct subspecialty strengths — understanding which is the right destination for your cancer type is the first step in accessing a meaningful second opinion.
| Centre | Location | Primary Strengths | Why Choose This Centre |
|---|---|---|---|
| Zhongshan Hospital, Fudan University | Shanghai | Hepatocellular carcinoma (HCC), liver surgery, hepatobiliary oncology, GI cancers | World's highest-volume HCC surgical programme; leading centre for TACE, HAIC, and liver resection outcomes data; liver transplant programme |
| Fudan University Shanghai Cancer Center (FUSCC) | Shanghai | Breast cancer, lung cancer, colorectal, head and neck, comprehensive oncology | Most internationally recognised dedicated cancer hospital in China; strong translational research; broad subspecialty depth; English-language international patient programme |
| Sun Yat-sen University Cancer Center (SYSUCC) | Guangzhou, Guangdong | Nasopharyngeal carcinoma (NPC), head and neck cancers, GI oncology, lung cancer | Asia's foremost NPC centre; developed and refined the standard-of-care chemoradiation protocol for NPC; highest NPC volume globally |
| Peking Union Medical College Hospital (PUMCH) | Beijing | Rare tumours, neuroendocrine, endocrine oncology, complex diagnostics | China's reference centre for rare and diagnostically complex tumours; strongest rare tumour and diagnostic second opinion capability |
| Beijing Cancer Hospital | Beijing | Gastric cancer, oesophageal cancer, lung cancer, GI oncology | China's highest-volume gastric and oesophageal cancer surgical programme; D2 gastrectomy and oesophagectomy expertise |
| Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) | Beijing | Comprehensive — national cancer reference centre | National comprehensive cancer centre; broadest access to China-based clinical trials; radiotherapy and surgical oncology depth |
China Cancer Centre Case Volumes vs International Benchmarks
Volume data contextualises why China's top centres offer subspecialist expertise depth that is difficult to replicate — particularly for tumour types with high incidence in East Asian populations.
Annual HCC / Liver Cancer Surgical Cases
Approximate annual hepatectomy volumes — HCC and other primary liver cancers. Source: institutional reports and published series.
- Zhongshan Hospital Shanghai>4,000/year
- SYSUCC Guangzhou>1,500/year
- Major US cancer centre (typical)200–500/year
- Major European centre (typical)150–350/year
Annual Nasopharyngeal Carcinoma New Cases
NPC incidence is 20–50× higher in Guangdong province than in Western countries — SYSUCC's volume is a direct product of this epidemiology.
- SYSUCC, Guangzhou>3,000/year
- Hong Kong regional centres combined~800/year
- Major UK cancer centre (typical)30–80/year
How CancerFax Facilitates a China Centre Second Opinion
Navigating a second opinion at a top Chinese hospital without support is challenging — language barriers, unfamiliar registration systems, and complex documentation requirements make independent access difficult. CancerFax removes all of these barriers.
- 1
Case Review and Centre Matching
CancerFax reviews your records and identifies whether Zhongshan Hospital, FUSCC, SYSUCC, or another Chinese centre is the strongest match for your cancer type and clinical question.
- 2
Medical Translation of Records
All submitted records (in any language) are medically translated into Chinese for submission to the receiving centre. CancerFax uses certified oncology-specialist translators — not general translation services.
- 3
Pre-Visit Remote Review Option
For patients who want an initial expert opinion before travelling, CancerFax can arrange a remote case review by the Chinese centre team — with English-language report delivered within 7–14 days. Many patients use this to confirm whether in-person travel adds value.
- 4
China Medical Visa and Travel Logistics
CancerFax provides the formal medical invitation letter required for the Chinese medical visa application, recommends direct flights to Shanghai (Pudong) or Guangzhou, and arranges accommodation and airport transfers.
- 5
In-Person Consultation with Bilingual Coordinator
Patient attends the Chinese hospital with a dedicated CancerFax bilingual coordinator — present at all consultations, ward rounds, and diagnostic appointments. The coordinator ensures nothing is lost in translation and advocates for the patient throughout the visit.
- 6
English Report and Follow-up
CancerFax obtains the clinical summary and second opinion recommendations from the Chinese team and delivers an English-language report to the patient. Follow-up communication between the Chinese centre and the patient's home oncologist is coordinated by CancerFax.
Frequently Asked Questions
Common questions from patients considering a cancer second opinion at Chinese specialist centres.
About China Centre Second Opinions
Do I need to speak Chinese to access a second opinion at these centres?
No — CancerFax provides dedicated bilingual medical coordinators who are present throughout the consultation process. All clinical communication, record translation, and report delivery is managed in English by CancerFax. You will never be in a medical consultation without full language support.
Which Chinese centre is best for liver cancer second opinions?
For hepatocellular carcinoma (HCC) specifically, Zhongshan Hospital is the strongest option — it performs over 4,000 liver surgeries per year and has published more outcome data on HCC resection and locoregional therapy than any centre outside Asia. For biliary tract cancers and cholangiocarcinoma, both Zhongshan and FUSCC have strong programmes. CancerFax will confirm the most appropriate centre based on your specific diagnosis.
Can a Chinese centre second opinion identify treatment options not available in my country?
Yes — this is one of the most clinically valuable aspects of a Chinese centre second opinion. Several targeted therapies and combination immunotherapy regimens are approved in China before Western regulators, particularly for HCC, gastric cancer, and nasopharyngeal carcinoma. Chinese centres also have access to clinical trials for China-developed agents not available in global cooperative trials. CancerFax identifies these options as part of the second opinion process.
How long do I need to stay in China for a second opinion?
An in-person second opinion at a Chinese cancer centre typically requires 2–5 days — covering the initial consultation, any additional investigations requested by the Chinese team (blood tests, additional imaging, biopsy if needed), and the follow-up discussion. CancerFax advises on the specific timeline for your case before travel.
More from the Cancer Second Opinion Resource Library
Explore related second opinion guides — from India centres to MD Anderson and liver cancer specifics.
- ↑ Cancer Second Opinion — Complete Guide
- Second Opinions for Liver Cancer and HCC: Why China's Centres Change Management
- Getting a Cancer Second Opinion at Tata Memorial Centre Mumbai
- Getting a Cancer Second Opinion at Apollo Hospitals India
- Getting a Second Opinion at MD Anderson: The International Patient Process
- Remote vs In-Person Cancer Second Opinions: How to Decide
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Access a China Cancer Centre Second Opinion Through CancerFax
CancerFax coordinates second opinion access at Zhongshan Hospital, FUSCC, and SYSUCC — managing records preparation, medical translation, appointment booking with the relevant subspecialist, and full logistics support for international patients travelling to Shanghai or Guangzhou.
This content is for informational purposes only and does not constitute medical advice. CancerFax is an access facilitation service — clinical decisions remain with the treating oncologist at the receiving centre.